Evidence map›Paper›PMID 30658124›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2019

Aligned microchannel polymer-nanotube composites for peripheral nerve regeneration: Small molecule drug delivery.

Ohan S Manoukian, Michael R Arul, Swetha Rudraiah, Ivo Kalajzic, Sangamesh G Kumbar

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 91 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Chiral MoSJournal of nanobiotechnology · 2024
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Nanocarrier-hydrogel composite delivery systems for precision drug release.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Ohan S ManoukianDepartment of Biomedical Engineering, University of Connecticut, Storrs, CT, USA; Department of Orthopaedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Michael R ArulDepartment of Orthopaedic Surgery, University of Connecticut Health, Farmington, CT, USA.
Swetha RudraiahDepartment of Orthopaedic Surgery, University of Connecticut Health, Farmington, CT, USA; Department of Pharmaceutical Sciences, University of Saint Joseph, Hartford, CT, USA.
Ivo KalajzicDepartment of Reconstructive Sciences, University of Connecticut Health, Farmington, CT, USA.
Sangamesh G KumbarDepartment of Biomedical Engineering, University of Connecticut, Storrs, CT, USA; Department of Orthopaedic Surgery, University of Connecticut Health, Farmington, CT, USA. Electronic address: kumbar@uchc.edu.
UConn Health · USUniversity of Connecticut · USUniversity of Saint Joseph · US

Funding

Notch Signaling and Bone Fracture HealingR01AR055607 · NIAMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Kurt David Hankenson, IVO Kalajzic · 2011 to 2026
$6.3M
Biodegradable Matrices for Bone HealingR01EB020640 · NIBIB · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI KUMBAR, SANGAMESH GURAPPA, YU, XIAOJUN · 2017 to 2020
$1.6M
NIAMS NIH HHS R01 AR055607NIBIB NIH HHS R01 EB020640
6 · The paper itself

Abstract

Peripheral nerve injury accounts for roughly 2.8% of all trauma patients with an annual cost of 7 billion USD in the U.S. alone. Current treatment options rely on surgical intervention with the use of an autograft, despite associated shortcomings. Engineered nerve guidance conduits, stem cell therapies, and transient electrical stimulation have reported to increase speeds of functional recovery. As an alternative to the conduction effects of electrical stimulation, we have designed and optimized a nerve guidance conduit with aligned microchannels for the sustained release of a small molecule drug that promotes nerve impulse conduction. A biodegradable chitosan structure reinforced with drug-loaded halloysite nanotubes (HNT) was formed into a foam-like conduit with interconnected, longitudinally-aligned pores with an average pore size of 59.3 ± 14.2 μm. The aligned composite with HNTs produced anisotropic mechanical behavior with a Young's modulus of 0.33 ± 0.1 MPa, very similar to that of native peripheral nerve. This manuscript reports on the sustained delivery of 4-Aminopyridine (4AP, molecular weight 94.1146 g/mol), a potassium-channel blocker as a growth factor alternative to enhance the rate of nerve regeneration. The conduit formulation released a total of 30 ± 2% of the encapsulated 4AP in the first 7 days. Human Schwann cells showed elevated expression of key proteins such as nerve growth factor, myelin protein zero, and brain derived neurotrophic factor in a 4AP dose dependent manner. Preliminary in vivo studies in a critical-sized sciatic nerve defect in Wistar rats confirmed conduit suturability and strength to withstand ambulatory forces over 4 weeks of their implantation. Histological evaluations suggest conduit biocompatibility and Schwann cell infiltration and organization within the conduit and lumen. These nerve guidance conduits and 4AP sustained delivery may serve as an attractive strategy for nerve repair and regeneration.

Indexed as

Drug Delivery SystemsNanotubes4-AminopyridineAnimalsCells, CulturedCell SurvivalChitosanClayDrug LiberationElastic ModulusFemaleHumansNerve RegenerationPotassium Channel BlockersRats, WistarSchwann Cells4-AminopyridineChitosanClayPotassium Channel BlockersHalloysite nanotubeNerve guidance conduitPeripheral nerve regenerationPolymer compositeSciatic nerve defectSmall molecule drug deliverySustained release

Identifiers

PMID30658124
PMCPMC6379151
OpenAlexW2911102657

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.